Injection therapies for nonbleeding disorders of the GI tract

Gastrointestinal Endoscopy

Volumn 64, Issue 3, 2006, Pages 399-411

  Yeh, Ronald W ^a   Triadafilopoulos, George ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BOTULINUM TOXIN; CORTICOSTEROID; CYANOACRYLATE; ENTERYX; ETHYLENE VINYL ALCOHOL COPOLYMER; FIBRIN GLUE; KETOCONAZOLE; OCTREOTIDE; PROTON PUMP INHIBITOR; STEROID; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; CANCER DIAGNOSIS; CARDIOESOPHAGOMYOTOMY; CLINICAL TRIAL; CORRELATION ANALYSIS; CRICOPHARYNGEUS MUSCLE; DENTAL ANESTHESIA; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM FISTULA; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; EATON LAMBERT SYNDROME; ELECTROMYOGRAPHY; ELECTRONIC MEDICAL RECORD; ENDOSCOPE; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SURGERY; ESOPHAGITIS; ESOPHAGUS ACHALASIA; ESOPHAGUS SPASM; ESOPHAGUS STRICTURE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL TRACT; HUMAN; LAPAROSCOPIC SURGERY; MANOMETRY; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RADIOFREQUENCY; REVIEW; SPHINCTEROTOMY; STOMACH CANCER; STOMACH EMPTYING; STOMACH PARESIS; SURGICAL TECHNIQUE; SUTURING METHOD; TREATMENT OUTCOME; VATER PAPILLA STENOSIS;

DIGESTIVE SYSTEM DISEASES; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL MOTILITY DISORDERS; GASTROINTESTINAL MOTILITY; HUMANS;

EID: 33747172018     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gie.2006.04.010     Document Type: Review

References (161)

1. In: McDonald J., Burroughs A., and Feagan B. (Eds). Evidence based gastroenterology and hepatology (1999), BMJ, London
2. Albanese A., Bentivoglio A.R., Cassetta E., et al. Review article: the use of botulinum toxin in the alimentary tract. Aliment Pharmacol Ther 9 (1995) 599-604
3. Jankovic J., and Brin M.F. Therapeutic uses of botulinum toxin. N Engl J Med 324 (1991) 1186-1194
4. Bhutani M.S. Gastrointestinal uses of botulinum toxin. Am J Gastroenterol 92 (1997) 929-933
5. Pamphlett R. Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci 92 (1989) 181-192
6. McKenna J.A., and Dedo H.H. Cricopharyngeal myotomy: indications and technique. Ann Otol Rhinol Laryngol 101 (1992) 216-221
7. Kelly J.H. Management of upper esophageal sphincter disorders: indications and complications of myotomy. Am J Med 108 Suppl 4a (2000) 43S-46S
8. Sewell R.K., and Bauman N.M. Congenital cricopharyngeal achalasia: management with botulinum toxin before myotomy. Arch Otolaryngol Head Neck Surg 131 (2005) 451-453
9. Murry T., Wasserman T., Carrau R.L., et al. Injection of botulinum toxin A for the treatment of dysfunction of the upper esophageal sphincter. Am J Otolaryngol 26 (2005) 157-162
10. Liu L.W., Tarnopolsky M., and Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol 18 (2004) 397-399
11. Marchese-Ragona R., Marioni G., Restivo D.A., et al. Solving dysphagia due to cricopharyngeal muscle dysfunction with botulinum toxin. Eur Arch Otorhinolaryngol 262 (2005) 250-251
12. Chiu M.J., Chang Y.C., and Hsiao T.Y. Prolonged effect of botulinum toxin injection in the treatment of cricopharyngeal dysphagia: case report and literature review. Dysphagia 19 (2004) 52-57
13. Parameswaran M.S., and Soliman A.M. Endoscopic botulinum toxin injection for cricopharyngeal dysphagia. Ann Otol Rhinol Laryngol 111 (2002) 871-874
14. Moerman M., Callier Y., Dick C., et al. Botulinum toxin for dysphagia due to cricopharyngeal dysfunction. Eur Arch Otorhinolaryngol 259 (2002) 1-3
15. Restivo D.A., Palmeri A., and Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease. N Engl J Med 346 (2002) 1174-1175
16. Haapaniemi J.J., Laurikainen E.A., Pulkkinen J., et al. Botulinum toxin in the treatment of cricopharyngeal dysphagia. Dysphagia 16 (2001) 171-175
17. Shaw G.Y., and Searl J.P. Botulinum toxin treatment for cricopharyngeal dysfunction. Dysphagia 16 (2001) 161-167
18. Brant C.Q., Siqueira E.S., and Ferrari Jr. A.P. Botulinum toxin for oropharyngeal dysphagia: case report of flexible endoscope-guided injection. Dis Esophagus 12 (1999) 68-73
19. Atkinson S.I., and Rees J. Botulinum toxin for cricopharyngeal dysphagia: case reports of CT-guided injection. J Otolaryngol 26 (1997) 273-276
20. Blitzer A., and Brin M.F. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. Otolaryngol Head Neck Surg 116 (1997) 328-330
21. Schneider I., Thumfart W.F., Pototschnig C., et al. Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol 103 (1994) 31-35
22. Feitoza A.B., Gostout C.J., Burgart L.J., et al. Hydroxypropyl methylcellulose: a better submucosal fluid cushion for endoscopic mucosal resection. Gastrointest Endosc 57 (2003) 41-47
23. Woltman T.A., Pellegrini C.A., and Oelschlager B.K. Achalasia. Surg Clin North Am 85 (2005) 483-493
24. Spechler S.J., and Castell D.O. Classification of oesophageal motility abnormalities. Gut 49 (2001) 145-151
25. Csendes A., Velasco N., Braghetto I., et al. A prospective randomized study comparing forceful dilatation and esophagomyotomy in patients with achalasia of the esophagus. Gastroenterology 80 (1981) 789-795
26. Csendes A., Braghetto I., Henriquez A., et al. Late results of a prospective randomised study comparing forceful dilatation and oesophagomyotomy in patients with achalasia. Gut 30 (1989) 299-304
27. Abir F., Modlin I., Kidd M., et al. Surgical treatment of achalasia: current status and controversies. Dig Surg 21 (2004) 165-176
28. Hoffman B.J., Knapple W.L., Bhutani M.S., et al. Treatment of achalasia by injection of botulinum toxin under endoscopic ultrasound guidance. Gastrointest Endosc 45 (1997) 77-79
29. Maiorana A., Fiorentino E., Genova E.G., et al. Echo-guided injection of botulinum toxin in patients with achalasia: initial experience. Endoscopy 31 (1999) S3-S4
30. Martinek J., and Spicak J. A modified method of botulinum toxin injection in patients with achalasia: a pilot trial. Endoscopy 35 (2003) 841-844
31. Martinek J., Siroky M., Plottova Z., et al. Treatment of patients with achalasia with botulinum toxin: a multicenter prospective cohort study. Dis Esophagus 16 (2003) 204-209
32. Annese V., Bassotti G., Coccia G., et al. A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut 46 (2000) 597-600
33. Allescher H.D., Storr M., Seige M., et al. Treatment of achalasia: botulinum toxin injection vs. pneumatic balloon dilation. A prospective study with long-term follow-up. Endoscopy 33 (2001) 1007-1017
34. Annese V., Basciani M., Borrelli O., et al. Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia. Muscle Nerve 21 (1998) 1540-1542
35. Annese V., Basciani M., Perri F., et al. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology 111 (1996) 1418-1424
36. Annese V., D'Onofrio V., and Andriulli A. Botulinum toxin in long-term therapy for achalasia. Ann Intern Med 128 (1998) 696
37. Bansal R., Nostrant T.T., Scheiman J.M., et al. Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary achalasia. J Clin Gastroenterol 36 (2003) 209-214
38. Cuilliere C., Ducrotte P., Zerbib F., et al. Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut 41 (1997) 87-92
39. Fishman V.M., Parkman H.P., Schiano T.D., et al. Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter. Am J Gastroenterol 91 (1996) 1724-1730
40. Gordon J.M., and Eaker E.Y. Prospective study of esophageal botulinum toxin injection in high-risk achalasia patients. Am J Gastroenterol 92 (1997) 1812-1817
41. Greaves R.R., Mulcahy H.E., Patchett S.E., et al. Early experience with intrasphincteric botulinum toxin in the treatment of achalasia. Aliment Pharmacol Ther 13 (1999) 1221-1225
42. Kolbasnik J., Waterfall W.E., Fachnie B., et al. Long-term efficacy of botulinum toxin in classical achalasia: a prospective study. Am J Gastroenterol 94 (1999) 3434-3439
43. Muehldorfer S.M., Schneider T.H., Hochberger J., et al. Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation. Endoscopy 31 (1999) 517-521
44. Pasricha P.J., Rai R., Ravich W.J., et al. Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology 110 (1996) 1410-1415
45. Vaezi M.F., Richter J.E., Wilcox C.M., et al. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial. Gut 44 (1999) 231-239
46. Wehrmann T., Kokabpick H., Jacobi V., et al. Long-term results of endoscopic injection of botulinum toxin in elderly achalasic patients with tortuous megaesophagus or epiphrenic diverticulum. Endoscopy 31 (1999) 352-358
47. Neubrand M., Scheurlen C., Schepke M., et al. Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy 34 (2002) 519-523
48. Andrews C.N., Anvari M., and Dobranowski J. Laparoscopic Heller's myotomy or botulinum toxin injection for management of esophageal achalasia. Patient choice and treatment outcomes. Surg Endosc 13 (1999) 742-746
49. Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 6 (1997) S146-S168
50. Mikaeli J., Fazel A., Montazeri G., et al. Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. Aliment Pharmacol Ther 15 (2001) 1389-1396
51. Zarate N., Mearin F., Baldovino F., et al. Achalasia treatment in the elderly: is botulinum toxin injection the best option?. Eur J Gastroenterol Hepatol 14 (2002) 285-290
52. Panaccione R., Gregor J.C., Reynolds R.P., et al. Intrasphincteric botulinum toxin versus pneumatic dilatation for achalasia: a cost minimization analysis. Gastrointest Endosc 50 (1999) 492-498
53. Zaninotto G., Annese V., Costantini M., et al. Randomized controlled trial of botulinum toxin versus laparoscopic Heller myotomy for esophageal achalasia. Ann Surg 239 (2004) 364-370
54. Zaninotto G., Vergadoro V., Annese V., et al. Botulinum toxin injection versus laparoscopic myotomy for the treatment of esophageal achalasia: economic analysis of a randomized trial. Surg Endosc 18 (2004) 691-695
55. Rosemurgy A., Villadolid D., Thometz D., et al. Laparoscopic Heller myotomy provides durable relief from achalasia and salvages failures after Botox or dilation. Ann Surg 241 (2005) 725-733 discussion 733-5
56. Dughera L., Battaglia E., Maggio D., et al. Botulinum toxin treatment of oesophageal achalasia in the old old and oldest old: a 1-year follow-up study. Drugs Aging 22 (2005) 779-783
57. Brisinda G., Civello I.M., Albanese A., et al. Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin. Curr Med Chem 10 (2003) 603-623
58. Triadafilopoulos G., and Tsang H.P. Olfactory stimuli provoke diffuse esophageal spasm: reversal by ipratropium bromide. Am J Gastroenterol 91 (1996) 2224-2227
59. Orlando R.C., and Bozymski E.M. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N Engl J Med 289 (1973) 23-25
60. Konturek J.W., Gillessen A., and Domschke W. Diffuse esophageal spasm: a malfunction that involves nitric oxide?. Scand J Gastroenterol 30 (1995) 1041-1045
61. Bortolotti M., Brunelli F., Sarti P., et al. Clinical and manometric effects of L-arginine in patients with chest pain and oesophageal motor disorders. Ital J Gastroenterol Hepatol 29 (1997) 320-324
62. Nasrallah S.M. Nifedipine in the treatment of diffuse oesophageal spasm. Lancet 2 (1982) 1285
63. Nasrallah S.M., Tommaso C.L., Singleton R.T., et al. Primary esophageal motor disorders: clinical response to nifedipine. South Med J 78 (1985) 312-315
64. Baunack A.R., and Weihrauch T.R. Clinical efficacy of nifedipine and other calcium antagonists in patients with primary esophageal motor dysfunctions. Arzneimittelforschung 41 (1991) 595-602
65. Konrad-Dalhoff I., Baunack A.R., Ramsch K.D., et al. Effect of the calcium antagonists nifedipine, nitrendipine, nimodipine and nisoldipine on oesophageal motility in man. Eur J Clin Pharmacol 41 (1991) 313-316
66. Richter J.E., Spurling T.J., Cordova C.M., et al. Effects of oral calcium blocker, diltiazem, on esophageal contractions. Studies in volunteers and patients with nutcracker esophagus. Dig Dis Sci 29 (1984) 649-656
67. Becker B.S., and Burakoff R. The effect of verapamil on the lower esophageal sphincter pressure in normal subjects and in achalasia. Am J Gastroenterol 78 (1983) 773-775
68. Cattau Jr. E.L., Castell D.O., Johnson D.A., et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 86 (1991) 272-276
69. Davies H.A., Lewis M.J., Rhodes J., et al. Trial of nifedipine for prevention of oesophageal spasm. Digestion 36 (1987) 81-83
70. Drenth J.P., Bos L.P., and Engels L.G. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther 4 (1990) 411-416
71. Clouse R.E., Lustman P.J., Eckert T.C., et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 92 (1987) 1027-1036
72. Cassidy M.J., Schiano T.D., Adrain A.L., et al. Botulinum toxin injection for the treatment of symptomatic diffuse esophageal spasm. Am J Gastroenterol 91 (1996) 1884
73. Miller L.S., Parkman H.P., Schiano T.D., et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci 41 (1996) 2025-2031
74. Miller L.S., Pullela S.V., Parkman H.P., et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol 97 (2002) 1640-1646
75. Nebendahl J.C., Brand B., von Schrenck T., et al. Effective treatment of diffuse esophageal spasm (DES) by endoscopic injection of botulinum toxin (BTX). [abstract]. Gastroenterology 114 (1998) A240
76. Storr M., Allescher H.D., Rösch T., et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injection of botulinum toxin: a prospective study with long term follow-up. [abstract]. Gastrointest Endosc 54 (2001) 18A
77. Camilleri M., Brown M.L., and Malagelada J.R. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 91 (1986) 94-99
78. Hoogerwerf W.A., Pasricha P.J., Kalloo A.N., et al. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 94 (1999) 1029-1033
79. Sturm A., Holtmann G., Goebell H., et al. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 60 (1999) 422-427
80. Bromer M.Q., Friedenberg F., Miller L.S., et al. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc 61 (2005) 833-839
81. Lacy B.E., Zayat E.N., Crowell M.D., et al. Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol 97 (2002) 1548-1552
82. Miller L.S., Szych G.A., Kantor S.B., et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 97 (2002) 1653-1660
83. Lacy B.E., Crowell M.D., Schettler-Duncan A., et al. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care 27 (2004) 2341-2347
84. Hogan W.J., and Geenen J.E. Biliary dyskinesia. Endoscopy 20 Suppl 1 (1988) 179-183
85. Sherman S., Troiano F.P., Hawes R.H., et al. Frequency of abnormal sphincter of Oddi manometry compared with the clinical suspicion of sphincter of Oddi dysfunction. Am J Gastroenterol 86 (1991) 586-590
86. Menees S., and Elta G.H. Sphincter of Oddi dysfunction. Curr Treat Options Gastroenterol 8 (2005) 109-115
87. Sherman S., Ruffolo T.A., Hawes R.H., et al. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 101 (1991) 1068-1075
88. Pasricha P.J., Miskovsky E.P., and Kalloo A.N. Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction. Gut 35 (1994) 1319-1321
89. Wehrmann T., Seifert H., Seipp M., et al. Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction. Endoscopy 30 (1998) 702-707
90. Banerjee B., Miedema B., Saifuddin T., et al. Intrasphincteric botulinum toxin type A for the diagnosis of sphincter of Oddi dysfunction: a case report. Surg Laparosc Endosc Percutan Tech 9 (1999) 194-196
91. Wehrmann T., Schmitt T.H., Arndt A., et al. Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction. Aliment Pharmacol Ther 14 (2000) 1469-1477
92. Muehldorfer S.M., Hahn E.G., and Ell C. Botulinum toxin injection as a diagnostic tool for verification of sphincter of Oddi dysfunction causing recurrent pancreatitis. Endoscopy 29 (1997) 120-124
93. Brisinda G., Maria G., Bentivoglio A.R., et al. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med 341 (1999) 65-69
94. Ron Y., Avni Y., Lukovetski A., et al. Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum 44 (2001) 1821-1826
95. Joo J.S., Agachan F., Wolff B., et al. Initial North American experience with botulinum toxin type A for treatment of anismus. Dis Colon Rectum 39 (1996) 1107-1111
96. Hallan R.I., Williams N.S., Melling J., et al. Treatment of anismus in intractable constipation with botulinum A toxin. Lancet II (1988) 714-717
97. Locke III G.R., Talley N.J., Fett S.L., et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112 (1997) 1448-1456
98. DeVault K.R., and Castell D.O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 190-200
99. Harris R.A., Kuppermann M., and Richter J.E. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med 102 (1997) 78-88
100. Hinder R.A., Filipi C.J., Wetscher G., et al. Laparoscopic Nissen fundoplication is an effective treatment for gastroesophageal reflux disease. Ann Surg 220 (1994) 472-481 discussion 481-3
101. Peters J.H., DeMeester T.R., Crookes P., et al. The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication: prospective evaluation of 100 patients with "typical" symptoms. Ann Surg 228 (1998) 40-50
102. Weerts J.M., Dallemagne B., Hamoir E., et al. Laparoscopic Nissen fundoplication: detailed analysis of 132 patients. Surg Laparosc Endosc 3 (1993) 359-364
103. Spechler S.J., Lee E., Ahnen D., et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285 (2001) 2331-2338
104. Edmundowicz S.A. Injection therapy of the lower esophageal sphincter for the treatment of GERD. Gastrointest Endosc 59 (2004) 545-552
105. Johnson D.A., Ganz R., Aisenberg J., et al. Endoscopic implantation of Enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial. Am J Gastroenterol 98 (2003) 1921-1930
106. Johnson D.A., Ganz R., Aisenberg J., et al. Endoscopic, deep mural implantation of Enteryx for the treatment of GERD: 6-month follow-up of a multicenter trial. Am J Gastroenterol 98 (2003) 250-258
107. Cohen L.B., Johnson D.A., Ganz R.A., et al. Enteryx implantation for GERD: expanded multicenter trial results and interim postapproval follow-up to 24 months. Gastrointest Endosc 61 (2005) 650-658
108. Schumacher B., Neuhaus H., Ortner M., et al. Reduced medication dependency and improved symptoms and quality of life 12 months after Enteryx implantation for gastroesophageal reflux. J Clin Gastroenterol 39 (2005) 212-219
109. Deviere J., Costamagna G., Neuhaus H., et al. Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial. Gastroenterology 128 (2005) 532-540
110. Schultz DG. FDA preliminary public health notification: recall of Boston Scientific ENTERYX® Procedure kits and ENTERYX® Injector Single Packs for treatment of gastroesophageal reflux disease (GERD). Available at: http://www.fda.gov/cdrh/safety/101405-enteryx.html.
111. Tintillier M., Chaput A., Kirch L., et al. Esophageal abscess complicating endoscopic treatment of refractory gastroesophageal reflux disease by Enteryx injection: a first case report. Am J Gastroenterol 99 (2004) 1856-1858
112. Wong R.F., Davis T.V., and Peterson K.A. Complications involving the mediastinum after injection of Enteryx for GERD. Gastrointest Endosc 61 (2005) 753-756
113. Spechler S. Complications of gastroesophageal reflux disease. In: Castell D. (Ed). The esophagus (1995), Little, Brown, Boston 533-544
114. Lee M., Kubik C.M., Polhamus C.D., et al. Preliminary experience with endoscopic intralesional steroid injection therapy for refractory upper gastrointestinal strictures. Gastrointest Endosc 41 (1995) 598-601
115. Zein N.N., Greseth J.M., and Perrault J. Endoscopic intralesional steroid injections in the management of refractory esophageal strictures. Gastrointest Endosc 41 (1995) 596-598
116. Kochhar R., and Makharia G.K. Usefulness of intralesional triamcinolone in treatment of benign esophageal strictures. Gastrointest Endosc 56 (2002) 829-834
117. Ramage Jr. J.I., Rumalla A., Baron T.H., et al. A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol 100 (2005) 2419-2425
118. Kochhar R., Ray J.D., Sriram P.V., et al. Intralesional steroids augment the effects of endoscopic dilation in corrosive esophageal strictures. Gastrointest Endosc 49 (1999) 509-513
119. Brooker J.C., Beckett C.G., Saunders B.P., et al. Long-acting steroid injection after endoscopic dilation of anastomotic Crohn's strictures may improve the outcome: a retrospective case series. Endoscopy 35 (2003) 333-337
120. Russell S.B., Trupin J.S., Myers J.C., et al. Differential glucocorticoid regulation of collagen mRNAs in human dermal fibroblasts. Keloid-derived and fetal fibroblasts are refractory to down-regulation. J Biol Chem 264 (1989) 13730-13735
121. Ashcraft K.W., and Holder T.M. The experimental treatment of esophageal strictures by intralesional steroid injections. J Thorac Cardiovasc Surg 58 (1969) 685-691 passim
122. Mendelsohn H.J., and Maloney W.H. The treatment of benign strictures of the esophagus with cortisone injection. Ann Otol Rhinol Laryngol 79 (1970) 900-904
123. Holder T.M., Ashcraft K.W., and Leape L. The treatment of patients with esophageal strictures by local steroid injections. J Pediatr Surg 4 (1969) 646-653
124. Tada M., Murakami A., Karita M., et al. Endoscopic resection of early gastric cancer. Endoscopy 25 (1993) 445-450
125. Uno Y., and Munakata A. The non-lifting sign of invasive colon cancer. Gastrointest Endosc 40 (1994) 485-489
126. Ishiguro A., Uno Y., Ishiguro Y., et al. Correlation of lifting versus non-lifting and microscopic depth of invasion in early colorectal cancer. Gastrointest Endosc 50 (1999) 329-333
127. Inoue H., Fukami N., Yoshida T., et al. Endoscopic mucosal resection for esophageal and gastric cancers. J Gastroenterol Hepatol 17 (2002) 382-388
128. Sumiyoshi T.F.T., Sumiyoshi Y., Matsuda T., et al. Injected substances to the submucosa in endoscopic mucosal resection: glycerin solution versus normal saline solution. [abstract]. Gastrointest Endosc 55 (2002) AB110
129. Uraoka T., Fujii T., Saito Y., et al. Effectiveness of glycerol as a submucosal injection for EMR. Gastrointest Endosc 61 (2005) 736-740
130. Conio M., Rajan E., Sorbi D., et al. Comparative performance in the porcine esophagus of different solutions used for submucosal injection. Gastrointest Endosc 56 (2002) 513-516
131. Fujishiro M., Yahagi N., Kashimura K., et al. Comparison of various submucosal injection solutions for maintaining mucosal elevation during endoscopic mucosal resection. Endoscopy 36 (2004) 579-583
132. Dick H.B. Evaluation of viscoelastic substances. J Cataract Refract Surg 27 (2001) 1711-1712
133. Lee S.H., Cho W.Y., Kim H.J., et al. A new method of EMR: submucosal injection of a fibrinogen mixture. Gastrointest Endosc 59 (2004) 220-224
134. Groitl H., and Scheele J. Initial experience with the endoscopic application of fibrin tissue adhesive in the upper gastrointestinal tract. Surg Endosc 1 (1987) 93-97
135. Chung M.A., and Wanebo H.J. Surgical management and treatment of gastric and duodenal fistulas. Surg Clin North Am 76 (1996) 1137-1146
136. Milde L.N. An anaphylactic reaction to fibrin glue. Anesth Analg 69 (1989) 684-686
137. Beierlein W., Scheule A.M., Antoniadis G., et al. An immediate, allergic skin reaction to aprotinin after reexposure to fibrin sealant. Transfusion 40 (2000) 302-305
138. Scheule A.M., Beierlein W., Lorenz H., et al. Repeated anaphylactic reactions to aprotinin in fibrin sealant. Gastrointest Endosc 48 (1998) 83-85
139. Joch C. The safety of fibrin sealants. Cardiovasc Surg 11 Suppl 1 (2003) 23-28
140. Fischer A., Benz S., Baier P., et al. Endoscopic management of pancreatic fistulas secondary to intraabdominal operation. Surg Endosc 18 (2004) 706-708
141. Shand A., Reading S., Ewing J., et al. Palliation of a malignant gastrocolic fistula by endoscopic human fibrin sealant injection. Eur J Gastroenterol Hepatol 9 (1997) 1009-1011
142. Shand A., Pendlebury J., Reading S., et al. Endoscopic fibrin sealant injection: a novel method of closing a refractory gastrocutaneous fistula. Gastrointest Endosc 46 (1997) 357-358
143. Papavramidis S.T., Eleftheriadis E.E., Apostolidis D.N., et al. Endoscopic fibrin sealing of high-output non-healing gastrocutaneous fistulas after vertical gastroplasty in morbidly obese patients. Obes Surg 11 (2001) 766-769
144. Huang C.S., Hess D.T., and Lichtenstein D.R. Successful endoscopic management of postoperative GI fistula with fibrin glue injection: report of two cases. Gastrointest Endosc 60 (2004) 460-463
145. Kurokawa T., Okushiba S., Kadoya M., et al. Selective occlusion with fibrin glue under fistuloscopy: seven cases of postoperative management for intractable complex fistulas. Endoscopy 34 (2002) 220-222
146. Rabago L.R., Ventosa N., Castro J.L., et al. Endoscopic treatment of postoperative fistulas resistant to conservative management using biological fibrin glue. Endoscopy 34 (2002) 632-638
147. Cellier C., Landi B., Faye A., et al. Upper gastrointestinal tract fistulae: endoscopic obliteration with fibrin sealant. Gastrointest Endosc 44 (1996) 731-733
148. Mok V.W., Ting A.C., Law S., et al. Combined endovascular stent grafting and endoscopic injection of fibrin sealant for aortoenteric fistula complicating esophagectomy. J Vasc Surg 40 (2004) 1234-1237
149. Singer A.J., and Thode Jr. H.C. A review of the literature on octylcyanoacrylate tissue adhesive. Am J Surg 187 (2004) 238-248
150. Eaglstein W.H., and Sullivan T. Cyanoacrylates for skin closure. Dermatol Clin 23 (2005) 193-198
151. Seewald S., Groth S., Sriram P.V., et al. Endoscopic treatment of biliary leakage with N-butyl-2 cyanoacrylate. Gastrointest Endosc 56 (2002) 916-919
152. Seewald S., Brand B., Groth S., et al. Endoscopic sealing of pancreatic fistula by using N-butyl-2-cyanoacrylate. Gastrointest Endosc 59 (2004) 463-470
153. Mutignani M., Tringali A., Khodadadian E., et al. External pancreatic fistulas resistant to conventional endoscopic therapy: endoscopic closure with N-butyl-2-cyanoacrylate (Glubran 2). Endoscopy 36 (2004) 738-742
154. Lee Y.C., Na H.G., Suh J.H., et al. Three cases of fistulae arising from gastrointestinal tract treated with endoscopic injection of Histoacryl. Endoscopy 33 (2001) 184-186
155. Seewald S., Groth S., Omar S., et al. Aggressive endoscopic therapy for pancreatic necrosis and pancreatic abscess: a new safe and effective treatment algorithm (videos). Gastrointest Endosc 62 (2005) 92-100
156. Nitsch A., Pabyk A., Honig J.F., et al. Cellular, histomorphologic, and clinical characteristics of a new octyl-2-cyanoacrylate skin adhesive. Aesthetic Plast Surg 29 (2005) 53-58
157. D'Onofrio V., Annese V., Miletto P., et al. Long-term follow-up of achalasic patients treated with botulinum toxin. Dis Esophagus 13 (2000) 96-101 discussion 102-3
158. Ezzeddine D., Jit R., Katz N., et al. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc 55 (2002) 920-923
159. Arts J., Gool S.J., Caenepeel P., et al. Effect of intrapyloric injection of botulinum toxin on gastric emptying and meal-related symptoms in gastroparesis. [abstract]. Gastroenterology 124 (2003) A431
160. Miyashita M., Onda M., Okawa K., et al. Endoscopic dexamethasone injection following balloon dilatation of anastomotic stricture after esophagogastrostomy. Am J Surg 174 (1997) 442-444
161. Lucha Jr. P.A., Fticsar J.E., and Francis M.J. The strictured anastomosis: successful treatment by corticosteroid injections-report of three cases and review of the literature. Dis Colon Rectum 48 (2005) 862-865